Acrux receives FDA approval for generic testosterone topical solution
Acrux Limited (ASX:ACR) (OTCMKTS:ARUXF)) has received US Food and Drug Administration (FDA) approval for its generic product based on Perrigos…
Börse:
36,000€
0,56%
Echtzeit-Aktienkurs Perrigo Company PLC
Bid:
36,000€
Ask:
36,000€
Nachrichtenticker der Perrigo Company PLC Aktie
Acrux receives FDA approval for generic testosterone topical solution
Acrux Limited (ASX:ACR) (OTCMKTS:ARUXF)) has received US Food and Drug Administration (FDA) approval for its generic product based on Perrigos Testosterone Topical Solution. In August 2018, Acrux submitted an Abbreviated New Drug Application (ANDA)...
Den vollständigen Artikel können Sie lesen unter: https://www.proactiveinvestors.com.au/companies/news/938138/acrux-receives-fda-approval-for-generic-testosterone-topical-solution-938138.html.
Den vollständigen Artikel können Sie lesen unter: https://www.proactiveinvestors.com.au/companies/news/938138/acrux-receives-fda-approval-for-generic-testosterone-topical-solution-938138.html.